Farag, Marwa Mohamed http://orcid.org/0000-0003-0426-9018
Hassan, Mohamed Ahmed Amen
Fasseeh, Nader Abd EL Moneim
Ghazal, Hesham Abd EL Rahim
Funding for this research was provided by:
Alexandria University
Article History
Received: 12 January 2024
Revised: 6 March 2024
Accepted: 8 March 2024
First Online: 4 May 2024
Declarations
:
: The study protocol has been approved by the Research Ethics Committee of Alexandria Faculty of Medicine, approval no.0201417 in 19–11-2020 (date of approval). IRB no. is 00012098 and FWA no. is 00018699.
: NHFOV can be used as an initial mode of ventilation in moderate and late preterm infants with moderate to severe RDS. NHFOV can provide CDP beyond the reported pressure limits of CPAP without causing neither CO2 retention nor an adverse hemodynamic effect. Except for increased respiratory secretion, NHFOV causes no significant respiratory adverse events.
: Written informed consent was obtained from parents or authorized legal representatives of all newborns who participated in the study.
: Written informed consent was obtained from parents or authorized legal representatives of all newborns who participated in the study for publication of anonymous patients’ data.
: The authors declare no competing interests.